These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 23931237)
1. Re: Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Atala A J Urol; 2013 Sep; 190(3):1132. PubMed ID: 23931237 [No Abstract] [Full Text] [Related]
2. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Wang X; Zhang L; O'Neill A; Bahamon B; Alsop DC; Mier JW; Goldberg SN; Signoretti S; Atkins MB; Wood CG; Bhatt RS Br J Cancer; 2013 Feb; 108(2):319-26. PubMed ID: 23322198 [TBL] [Abstract][Full Text] [Related]
3. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Sun M; Trinh QD; Perrotte P; Karakiewicz PI Eur Urol; 2014 May; 65(5):1014-5. PubMed ID: 24646500 [No Abstract] [Full Text] [Related]
4. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Ouzaid I; Rini B Eur Urol; 2014 Mar; 65(3):667-8. PubMed ID: 24484761 [No Abstract] [Full Text] [Related]
5. Pazopanib versus sunitinib in renal cancer. Casper J; Schumann-Binarsch S; Köhne CH N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224638 [No Abstract] [Full Text] [Related]
6. Pazopanib versus sunitinib in renal cancer. Wittes J N Engl J Med; 2013 Nov; 369(20):1969. PubMed ID: 24224637 [No Abstract] [Full Text] [Related]
7. Pazopanib versus sunitinib in renal cancer. Ramaekers R; Tharnish M; Copur MS N Engl J Med; 2013 Nov; 369(20):1968-9. PubMed ID: 24224636 [No Abstract] [Full Text] [Related]
8. Pazopanib versus sunitinib in renal cancer. Motzer RJ; McCann L; Deen K N Engl J Med; 2013 Nov; 369(20):1970. PubMed ID: 24224635 [No Abstract] [Full Text] [Related]
9. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. Motzer RJ; Hutson TE; McCann L; Deen K; Choueiri TK N Engl J Med; 2014 May; 370(18):1769-70. PubMed ID: 24785224 [No Abstract] [Full Text] [Related]
10. Benefits of pazopanib over sunitinib for renal cell carcinoma. Granovetter M Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821 [No Abstract] [Full Text] [Related]
11. Pazopanib outscores sunitinib on tolerability. Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960 [TBL] [Abstract][Full Text] [Related]
13. Word of wisdom. Re: clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. Zigeuner R Eur Urol; 2014 Oct; 66(4):785. PubMed ID: 25218072 [No Abstract] [Full Text] [Related]
18. Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. Annala M; Nappi L; Azad AA; Mo F; Fazli L; Chi KN; Wyatt AW Clin Genitourin Cancer; 2017 Feb; 15(1):e145-e150. PubMed ID: 27324055 [No Abstract] [Full Text] [Related]
19. Decreased toxicity with 2 weeks on and 1 week off schedule of sunitinib in metastatic renal cell carcinoma: is it a mirage or an oasis? Malik L Eur J Cancer; 2014 Aug; 50(12):2171-2. PubMed ID: 24930626 [No Abstract] [Full Text] [Related]
20. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Narayanan S; Callis-Duffin K; Batten J; Agarwal N Am J Med Sci; 2010 Jun; 339(6):580-1. PubMed ID: 20421784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]